Accordingly, blocking the action of IL-1β or TNF-α with an antibody directed against the IL-1β receptor or a TNF-α inactivating fusion protein results in a reduction of LPS-induced cholestasis [8–12], which was almost completely abolished by combined inactivation of IL-1β and TNF-α [13]. The gene discussed is IL1B; the disease is cholestasis.